José A García-Sáenz

Summary

Publications

  1. pmc SEOM clinical guidelines in early-stage breast cancer 2015
    J A Garcia-Saenz
    Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 17:939-45. 2015
  2. pmc Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot
    EORTC, Soft Tissue and Bone Sarcoma Group, Centre Léon Bérard and Université Claude Bernard, Lyon, France
    BMC Cancer 14:166. 2014
  3. ncbi Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
  4. ncbi Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
    José A García-Sáenz
    Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:676-80. 2006
  5. ncbi Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
    Jose Angel Garcia-Saenz
    Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
    Clin Transl Oncol 8:826-9. 2006
  6. ncbi Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid
    Jose Angel Garcia Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Oral Patol Oral Cir Bucal 12:E351-6. 2007
  7. ncbi Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
  8. ncbi Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:737-47. 2009
  9. doi Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
    José A García-Sáenz
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 13:121-32. 2011
  10. ncbi Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
    Javier Puente Vázquez
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:50-3. 2006

Collaborators

Detail Information

Publications14

  1. pmc SEOM clinical guidelines in early-stage breast cancer 2015
    J A Garcia-Saenz
    Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 17:939-45. 2015
    ..In these guidelines, we summarize current evidence for the medical management of early-stage breast cancer. ..
  2. pmc Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot
    EORTC, Soft Tissue and Bone Sarcoma Group, Centre Léon Bérard and Université Claude Bernard, Lyon, France
    BMC Cancer 14:166. 2014
    ..This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC)...
  3. ncbi Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
    ..To determine the activity of successive trastuzumab-containing regimens in HER2-overexpressing metastatic breast cancer (MBC) as well as the response rate (RR), time to progression (TTP), and predictive factors for response...
  4. ncbi Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
    José A García-Sáenz
    Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:676-80. 2006
    ..Immunohistochemistry is being explored to detect undetectable microscopic lymph node micrometastases...
  5. ncbi Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
    Jose Angel Garcia-Saenz
    Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
    Clin Transl Oncol 8:826-9. 2006
    ..The relationship between breast cancer and circadian rhythm variation has been extensively studied. Increased breast tumorigenesis has been reported in melatonin-suppressed experimental models and in observational studies...
  6. ncbi Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid
    Jose Angel Garcia Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Oral Patol Oral Cir Bucal 12:E351-6. 2007
    ..Here we report our findings on all 2005 OJN cases presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence of ONJ is nearly 3% (3 out of 104) in these patients...
  7. ncbi Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
    ..Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration...
  8. ncbi Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:737-47. 2009
    ..Such patterns may be a novel and cost-effective tool to develop tailored treatments. This manuscript will review biomarkers and molecular pathways that are involved in the tumour response to anti-EGFR therapies...
  9. doi Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
    José A García-Sáenz
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 13:121-32. 2011
    ..Suboptimal survival results have led to major efforts to identify prognostic factors, improve surgical staging and develop adjuvant therapies to improve patients' outcomes...
  10. ncbi Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
    Javier Puente Vázquez
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:50-3. 2006
    ..CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies...
  11. ncbi Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
    Carlos Jara-Sánchez
    Unidad de Oncología Médica, Fundacion Hospital Alcorcon, Madrid, Spain
    Clin Breast Cancer 3:399-404. 2003
    ..However, the results do not indicate clear advantages compared to the conventional weekly scheme of administration...
  12. doi Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
    Milagros Gonzalez-Rivera
    Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón IiSGM, Hospital General Universitario Gregorio Maranon, Madrid, Spain
    Breast Cancer Res Treat 156:507-15. 2016
    ..However, no definitive conclusions can be reached due to the low prevalence and the uncertain clinical impact of most of the genes included...
  13. doi Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease
    Atocha Romero
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain Medical Oncology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain Electronic address
    Transl Res 166:783-7. 2015
    ....
  14. pmc BRCA1 Alternative splicing landscape in breast tissue samples
    Atocha Romero
    Molecular Oncology Laboratoy, Instituto de Investigación Sanitaria San Carlos Center affiliated to the Red Temática de Investigación Cooperativa RD12 0036 006, Instituto Carlos III, Spanish Ministry of Economy and Competitivy, 28040, Madrid, Spain
    BMC Cancer 15:219. 2015
    ..However, BRCA1 splicing pattern in breast tissue samples is unknown. Here, we provide an accurate description of BRCA1 splicing events distribution in breast tissue samples...